Gossamer Bio Reports Q1 2025 Results and Study Updates

Gossamer Bio ( (GOSS) ) has released its Q1 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors.

Gossamer Bio is a late-stage clinical biopharmaceutical company focused on developing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

In its latest earnings report, Gossamer Bio announced the closure of new patient screening for its Phase 3 PROSERA Study in PAH, with enrollment expected to complete in early June. The company also highlighted its financial results for the first quarter of 2025, alongside strategic updates on its clinical trials.

Key highlights from the report include the anticipated announcement of topline results from the PROSERA Study in February 2026 and the planned activation of clinical sites for the Phase 3 SERANATA Study in PH-ILD in the fourth quarter of 2025. Financially, Gossamer Bio reported cash, cash equivalents, and marketable securities totaling $258 million as of March 31, 2025, and a net loss of $36.6 million for the quarter, an improvement from the previous year’s loss.

The company’s strategic focus remains on advancing its clinical trials, with the PROSERA Study aiming to evaluate seralutinib’s efficacy in improving six-minute walk distance among PAH patients. The SERANATA Study will explore similar endpoints for PH-ILD patients, with regulatory alignment achieved with both the FDA and EMA.

Looking ahead, Gossamer Bio is optimistic about its clinical developments and financial stability, with current resources expected to fund operations into the first half of 2027. The company remains committed to its mission of addressing unmet needs in pulmonary hypertension treatment.